Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PPM1D
REST API REST API
Homo sapiens
PPM1D is differentially expressed in 271 experiments: 100 organism parts: cerebellum, liver, ... (98 more);, 128 disease states: normal, control, ... (126 more);, 79 cell types 333 cell lines 40 compound treatments and 61 other conditions.
Synonyms Wip1, PP2C-DELTA
Orthologs ppm1d (Danio rerio)   PPM1D (1 of 2) (Danio rerio)   PTC3 (Saccharomyces cerevisiae)   Ppm1d (Mus musculus)   PTC2 (Saccharomyces cerevisiae)   PPM1D (Gallus gallus)   Ppm1d (Rattus norvegicus)   ENSCING00000007208 (Ciona intestinalis)   E1BD03_BOVIN (Bos taurus)   Pp2C1 (Drosophila melanogaster)   ppm1d (Xenopus laevis)   PPM1D (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, negative regulation of cell proliferation, metal ion binding, protein serine/threonine phosphatase activity, protein serine/threonine phosphatase complex, cell cycle, response to bacterium, nucleus, G2/M transition of mitotic cell cycle, hydrolase activity, catalytic activity, response to radiation, protein dephosphorylation
InterPro Term PP2C-like
UniProt Accession O15297, Q8IVR6, B4DSJ4
Gene-Disease Assocation BREAST CANCER
Search EB-eye ENSG00000170836
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
MCF-7
1
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
Daudi
2
E-MTAB-37, E-GEOD-96
327 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (40 experiments)

Factor Value U/D Experiments
1
2
E-TABM-130, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-MTAB-24
CD105+ endothelial
1
1
E-AFMX-5
wild_type
1
E-GEOD-20193
eosinophil
1
E-GEOD-3982
spheroid recovery
1
E-GEOD-4219
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-21912, E-GEOD-20602, E-GEOD-8121, E-GEOD-16363
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-GEOD-2514
neuroblastoma
2
E-MTAB-37, E-MTAB-62
squamous cell carcinoma
2
E-MTAB-37, E-MTAB-62
subependymal giant cell astrocytoma
1
E-MEXP-2351
122 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-697, E-TABM-782, E-GEOD-3720, E-MEXP-1958, ... (26 experiments)

Factor Value U/D Experiments
none
2
5
E-MEXP-1230, E-GEOD-412, E-MEXP-1958, E-TABM-782, E-GEOD-697, ... (7 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
LDL
1
E-GEOD-5741
unknown
1
E-GEOD-7307
tBHP
1
E-MEXP-2345
Cxcl12
1
E-GEOD-7307
34 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
43
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-MEXP-2283, E-MEXP-958, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-GEOD-22148, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, E-TABM-321, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20540, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-1561

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.413 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM